In addition, a reduction in type 17 immune activity has been linked to dermatophytosis (invasive or chronic) susceptibility, as has been indicated in adult T-cell leukemia/lymphoma (ATLL) individuals (164), those with STAT3-related malfunction (163), patients with gain-of-function (GOF) mutations (165), and those receiving anti-IL-17 antibody-related therapy (i.e., secukinumab and ixekizumab) (166–168). Here, STAT3 is linked to dermatophytosis.